Physicochemical Properties
| Molecular Formula | C21H24CLN5O2 |
| Molecular Weight | 413.90 |
| CAS # | 2641930-61-0 |
| Related CAS # | FNDR-20123 free base;1267502-34-0 |
| Appearance | White to yellow solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | human HDAC 3 nM (IC50) Plasmodium HDAC 31 nM (IC50) HDAC1 25 nM (IC50) HDAC2 29 nM (IC50) HDAC3 2 nM (IC50) HDAC6 11 nM (IC50) HDAC8 282 nM (IC50) Plasmodium |
| ln Vitro | FNDR-20123 is effective against every resistant strain that has been studied thus far, which will be very helpful in getting rid of the rapidly spreading parasite that is resistant to drugs[1]. |
| ln Vivo | In addition, FNDR-20123 (10–50 mg/kg; po; bw for 4 days) can considerably lower parasitaemia in a mouse model of P. falciparum infection[1]. |
| Animal Protocol |
Animal/Disease Models: P. falciparum Pf3D70087/N9 in NODscidIL2Rγnull mice (engrafted with human erythrocytes)[1] Doses: 10 and 50 mg/kg Route of Administration: Po; bw for 4 days Experimental Results: Resulted in a significant reduction in parasitaemia with 6.5% and 2.57% parasitaemia at 10 and 50 mg/kg, respectively. |
| References |
[1]. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malar J. 2020;19(1):365. Published 2020 Oct 12. |
Solubility Data
| Solubility (In Vitro) | DMSO : 31.25 mg/mL (75.50 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4160 mL | 12.0802 mL | 24.1604 mL | |
| 5 mM | 0.4832 mL | 2.4160 mL | 4.8321 mL | |
| 10 mM | 0.2416 mL | 1.2080 mL | 2.4160 mL |